Tetanus toxin explained

Symbol:tetX
Organism:Clostridium tetani E88
Taxid:212717
Uniprot:P04958
Entrezgene:24255210
Refseqprotein:WP_011100836.1
Chromosome:Genomic
Entrezchromosome:NC_004565.1
Genloc Start:68047
Genloc End:73178
Tentoxilysin
Ec Number:3.4.24.68
Cas Number:107231-12-9

Tetanus toxin (TeNT) is an extremely potent neurotoxin produced by the vegetative cell of Clostridium tetani in anaerobic conditions, causing tetanus. It has no known function for clostridia in the soil environment where they are normally encountered. It is also called spasmogenic toxin, tentoxilysin, tetanospasmin, or tetanus neurotoxin. The LD50 of this toxin has been measured to be approximately 2.5 - 3 ng/kg,[1] [2] making it second only to the related botulinum toxin (LD50 2 ng/kg)[3] as the deadliest toxin in the world. However, these tests are conducted solely on mice, which may react to the toxin differently from humans and other animals.

C. tetani also produces the exotoxin tetanolysin, a hemolysin, that causes destruction of tissues.[4]

Distribution

Tetanus toxin spreads through tissue spaces into the lymphatic and vascular systems. It enters the nervous system at the neuromuscular junctions and migrates through nerve trunks and into the central nervous system (CNS) by retrograde axonal transport by using dyneins.[5] [6]

Structure

The tetanus toxin protein has a molecular weight of 150 kDa. It is translated from the tetX gene as one protein which is subsequently cleaved into two parts: a 100 kDa heavy or B-chain and a 50 kDa light or A-chain. The chains are connected by a disulfide bond.

The TetX gene encoding this protein is located on the PE88 plasmid.[7] [8]

Several structures of the binding domain and the peptidase domain have been solved by X-ray crystallography and deposited in the PDB.[9]

Mechanism of action

The mechanism of TeNT action can be broken down and discussed in these different steps:

Transport
  1. Specific binding in the periphery neurons
  1. Retrograde axonal transport to the CNS inhibitory interneurons
  1. Transcytosis from the axon into the inhibitory interneurons
Action
  1. Temperature- and pH-mediated translocation of the light chain into the cytosol
  1. Reduction of the disulfide bridge to thiols, severing the link between the light and heavy chain
  1. Cleavage of synaptobrevin at -Gln76-Phe- bond

The first three steps outline the travel of tetanus toxin from the peripheral nervous system to where it is taken up to the CNS and has its final effect. The last three steps document the changes necessary for the final mechanism of the neurotoxin.

Transport to the CNS inhibitory interneurons begins with the B-chain mediating the neurospecific binding of TeNT to the nerve terminal membrane. It binds to GT1b polysialogangliosides, similarly to the C. botulinum neurotoxin. It also binds to another poorly characterized GPI-anchored protein receptor more specific to TeNT.[10] [11] Both the ganglioside and the GPI-anchored protein are located in lipid microdomains and both are requisite for specific TeNT binding. Once it is bound, the neurotoxin is then endocytosed into the nerve and begins to travel through the axon to the spinal neurons. The next step, transcytosis from the axon into the CNS inhibitory interneuron, is one of the least understood parts of TeNT action. At least two pathways are involved, one that relies on the recycling of synaptic vesicle 2 (SV2) system and one that does not.[12]

Once the vesicle is in the inhibitory interneuron, its translocation is mediated by pH and temperature, specifically a low or acidic pH in the vesicle and standard physiological temperatures.[13] [14] Once the toxin has been translocated into the cytosol, chemical reduction of the disulfide bond to separate thiols occurs, mainly by the enzyme NADPH-thioredoxin reductase-thioredoxin. The light chain is then free to cleave the Gln76-Phe77 bond of synaptobrevin.[15] Cleavage of synaptobrevin affects the stability of the SNARE core by restricting it from entering the low-energy conformation, which is the target for NSF binding.[16] Synaptobrevin is an integral V-SNARE necessary for vesicle fusion to membranes. The final target of TeNT is the cleavage of synaptobrevin and, even in low doses, has the effect of interfering with exocytosis of neurotransmitters from inhibitory interneurons. The blockage of the neurotransmitters γ-aminobutyric acid (GABA) and glycine is the direct cause of the physiological effects that TeNT induces. GABA inhibits motor neurons, so by blocking GABA, tetanus toxin causes violent spastic paralysis.[17] The action of the A-chain also stops the affected neurons from releasing excitatory transmitters,[18] by degrading the protein synaptobrevin 2.[19] The combined consequence is dangerous overactivity in the muscles from the smallest sensory stimuli, as the damping of motor reflexes is inhibited, leading to generalized contractions of the agonist and antagonist musculature, termed a "tetanic spasm".

Clinical significance

The clinical manifestations of tetanus are caused when tetanus toxin blocks inhibitory impulses, by interfering with the release of neurotransmitters, including glycine and gamma-aminobutyric acid. These inhibitory neurotransmitters inhibit the alpha motor neurons. With diminished inhibition, the resting firing rate of the alpha motor neuron increases, producing rigidity, unopposed muscle contraction and spasm. Characteristic features are risus sardonicus (a rigid smile), trismus (commonly known as "lock-jaw"), and opisthotonus (rigid, arched back). Seizures may occur, and the autonomic nervous system may also be affected. Tetanospasmin appears to prevent the release of neurotransmitters by selectively cleaving a component of synaptic vesicles called synaptobrevin II.[20] Loss of inhibition also affects preganglionic sympathetic neurons in the lateral gray matter of the spinal cord and produces sympathetic hyperactivity and high circulating catecholamine levels. Hypertension and tachycardia alternating with hypotension and bradycardia may develop.[21] [22]

Tetanic spasms can occur in a distinctive form called opisthotonos and be sufficiently severe to fracture long bones. The shorter nerves are the first to be inhibited, which leads to the characteristic early symptoms in the face and jaw, risus sardonicus and lockjaw.

Immunity and vaccination

Due to its extreme potency, even a lethal dose of tetanospasmin may be insufficient to provoke an immune response. Naturally acquired tetanus infections thus do not usually provide immunity to subsequent infections. Immunization (which is impermanent and must be repeated periodically) instead uses the less deadly toxoid derived from the toxin, as in the tetanus vaccine and some combination vaccines (such as DTP).

Evolution

Very little has been written or researched on how and why tetanospasmin evolved in animals. The toxin is highly specific to muscular neurons in higher animals and is carried by a plasmid which implies that the host bacterium acquired the plasmid through horizontal gene transfer from another source organism as is the case of most plasmid based toxins such as shigatoxin. Although tetanospasmin is now classified as an extremely potent neurotoxin, its evolutionary origins may indicate it may have served an entirely different function in early animal life. It is routinely carried by anaerobic organisms and early life on earth was typically capable of both aerobic and anaerobic respiration. Human DNA still contains all the genes necessary for anaerobic respiration and one example is the lens cells of the human eye, which still operate in anaerobic mode.[23]

Most lower animals, and even some mammals are capable of anaerobic respiration during their hibernation phases. The spasms typically caused by this toxin mimic cardiac rhythms in skeletal muscles in most reptiles exposed to the toxin and would provide an evolutionary advantage to a hibernating reptile by keeping blood moving slowly around the organism while in hibernation mode if the organism switched to anaerobic respiration. This theory is supported by the fact that tetanus bacteria use a "pump and dump" strategy by secreting the toxin inside a plasmid membrane then exocysing the plasmid vacuole into target tissue. The toxin is not immediately released typically.[24] Higher mammals host this bacteria as a common component of intestinal gut flora and mouth bacteria without any ill effects and it only becomes a problem in anaerobic conditions.[25]

It has no currently known function in the bacterium's host environment which is soil and manure and is harmless to any competing organisms. It only affects higher animals which have neuro muscular junctions which makes its very existence a mystery to modern science.

Further reading

Notes and References

  1. Web site: Pinkbook Tetanus Epidemiology of Vaccine Preventable Diseases . CDC . en-us. 2017-01-18.
  2. Web site: Toxin Table . Environmental Health & Safety » University of Florida . en. 2017-01-18. 2017-01-18. https://web.archive.org/web/20170118221643/http://www.ehs.ufl.edu/programs/bio/toxins/toxin-table/. dead.
  3. Web site: Botulism. World Health Organization. en-GB. 2017-01-18.
  4. Book: Willey J . Prescott's Principles of Microbiology. limited. 2009. McGraw-Hill. New York City, NY. 978-0-07-337523-6. 481.
  5. Farrar JJ, Yen LM, Cook T, Fairweather N, Binh N, Parry J, Parry CM . Tetanus . Journal of Neurology, Neurosurgery, and Psychiatry . 69 . 3 . 292–301 . September 2000 . 10945801 . 1737078 . 10.1136/jnnp.69.3.292 .
  6. Lalli G, Gschmeissner S, Schiavo G . Myosin Va and microtubule-based motors are required for fast axonal retrograde transport of tetanus toxin in motor neurons . Journal of Cell Science . 116 . Pt 22 . 4639–4650 . November 2003 . 14576357 . 10.1242/jcs.00727 . free .
  7. Eisel U, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Habermann E, Niemann H . Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins . The EMBO Journal . 5 . 10 . 2495–2502 . October 1986 . 3536478 . 1167145 . 10.1002/j.1460-2075.1986.tb04527.x .
  8. Popp D, Narita A, Lee LJ, Ghoshdastider U, Xue B, Srinivasan R, Balasubramanian MK, Tanaka T, Robinson RC . Novel actin-like filament structure from Clostridium tetani . The Journal of Biological Chemistry . 287 . 25 . 21121–21129 . June 2012 . 22514279 . 3375535 . 10.1074/jbc.M112.341016 . free .
  9. Web site: Advanced Search for UniProt ID P04958 . Protein Databank in Europe (PDBe) .
  10. Munro P, Kojima H, Dupont JL, Bossu JL, Poulain B, Boquet P . High sensitivity of mouse neuronal cells to tetanus toxin requires a GPI-anchored protein . Biochemical and Biophysical Research Communications . 289 . 2 . 623–629 . November 2001 . 11716521 . 10.1006/bbrc.2001.6031 .
  11. Winter A, Ulrich WP, Wetterich F, Weller U, Galla HJ . Gangliosides in phospholipid bilayer membranes: interaction with tetanus toxin . Chemistry and Physics of Lipids . 81 . 1 . 21–34 . June 1996 . 9450318 . 10.1016/0009-3084(96)02529-7 .
  12. Yeh FL, Dong M, Yao J, Tepp WH, Lin G, Johnson EA, Chapman ER . SV2 mediates entry of tetanus neurotoxin into central neurons . PLOS Pathogens . 6 . 11 . e1001207 . November 2010 . 21124874 . 2991259 . 10.1371/journal.ppat.1001207 . free .
  13. Pirazzini M, Rossetto O, Bertasio C, Bordin F, Shone CC, Binz T, Montecucco C . Time course and temperature dependence of the membrane translocation of tetanus and botulinum neurotoxins C and D in neurons . Biochemical and Biophysical Research Communications . 430 . 1 . 38–42 . January 2013 . 23200837 . 10.1016/j.bbrc.2012.11.048 .
  14. Burns JR, Baldwin MR . Tetanus neurotoxin utilizes two sequential membrane interactions for channel formation . The Journal of Biological Chemistry . 289 . 32 . 22450–22458 . August 2014 . 24973217 . 4139251 . 10.1074/jbc.m114.559302 . free .
  15. Pirazzini M, Bordin F, Rossetto O, Shone CC, Binz T, Montecucco C . The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals . FEBS Letters . 587 . 2 . 150–155 . January 2013 . 23178719 . 10.1016/j.febslet.2012.11.007 . free .
  16. Pellegrini LL, O'Connor V, Lottspeich F, Betz H . Clostridial neurotoxins compromise the stability of a low energy SNARE complex mediating NSF activation of synaptic vesicle fusion . The EMBO Journal . 14 . 19 . 4705–4713 . October 1995 . 7588600 . 394567 . 10.1002/j.1460-2075.1995.tb00152.x .
  17. Book: Kumar V, Abbas AK, Fausto N, Aster JC . Robbins and Cotran Pathologic Basis of Disease . Professional: Expert Consult - Online Kindle . Elsevier Health .
  18. Kanda K, Takano K . Effect of tetanus toxin on the excitatory and the inhibitory post-synaptic potentials in the cat motoneurone . The Journal of Physiology . 335 . 319–333 . February 1983 . 6308220 . 1197355 . 10.1113/jphysiol.1983.sp014536 .
  19. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C . Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin . Nature . 359 . 6398 . 832–835 . October 1992 . 1331807 . 10.1038/359832a0 . 4241066 . 1992Natur.359..832S .
  20. Book: Todar K . 2005 . http://textbookofbacteriology.net/clostridia_3.html . 24 June 2018 . Pathogenic Clostridia, including Botulism and Tetanus . Todar's Online Textbook of Bacteriology.
  21. Book: Loscalzo J, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL . Harrison's principles of internal medicine . McGraw-Hill Medical . 2008 . 978-0-07-146633-2 .
  22. Web site: Yabes Jr JM, McLaughlin R . Brusch JL . Tetanus in Emergency Medicine . Emedicine . 2011-09-01.
  23. Book: Whikehart DR . Biochemistry of the Eye . 2003 . Butterworth-Heinemann . Boston . 0-7506-7152-1 . 107–108 . 2nd.
  24. Popoff MR . Tetanus in animals . Journal of Veterinary Diagnostic Investigation . 32 . 2 . 184–191 . March 2020 . 32070229 . 10.1177/1040638720906814 . SAGE Publications . 7081504 .
  25. Hao NV, Huyen NN, Ny NT, Trang VT, Hoang NV, Thuy DB, Nguyen NT, Lieu PT, Duong HT, Thuy TT, Nhat PT, Tam DT, Boni MF, Yen LM, Tan LV, Thanh TT, Campbell J, Thwaites CL . The Role of the Gastrointestinal Tract in Toxigenic Clostridium tetani Infection: A Case-Control Study . The American Journal of Tropical Medicine and Hygiene . 105 . 2 . 494–497 . June 2021 . 34181568 . 10.4269/ajtmh.21-0146 . American Society of Tropical Medicine and Hygiene . 8437200 .